Laurus Labs Ltd Q1 FY27 Earnings Analysis

- Laurus Labs expects continued strong growth next year with the order book well in place (Soumya Chava). - CDMO business is growing robustly with several late-stage clinical programs; some are anticipated to commercialize in FY '27 (Krishna Chaitanya Chava). - CDMO revenues are targeted to reach 50% of overall sales by 2030 (Satyanarayana Chava). - ARV sales volume is expected to remain roughly constant (~INR 2,800 crores), but its percentage contribution to revenue will decline as CDMO grows (Satyanarayana Chava). - Expansion plans include significant capex (~INR 1,500 crores annually, increased from INR 1,000 crores) focused on growth and capacity tied to confirmed customer demand (Satyanarayana Chava). - Affordable Medicines division grew 18% in FY '26, with steady outlook driven by volume increases and new product launches (Soumya Chava). - The fermentation capacity and formulation expansions aim to support volume growth across segments.

- Laurus Labs expects continued strong growth, particularly in the CDMO segment, with CDMO revenues projected to reach 50% of overall sales by FY2030. - EBITDA margins improved to 26.8% in FY '26 and are expected to be maintained or improved in FY '27, with Q4 EBITDA margin reaching nearly 29%. - Operational leverage is anticipated to play a bigger role over the next 1-2 years as capacities expand, supporting margin improvement. - Growth in CDMO is expected to be steady, driven by a robust pipeline and multiple commercial products, mitigating concentration and destocking risks. - Affordable Medicines segment grew 18% in FY '26 and is expected to maintain steady growth. - Profit after tax surged 148% in FY '26, with continuing focus on R&D and capacity expansion supporting future earnings growth. - Return ratios and margins benefit from visible growth capex backed by secured orders, signaling improved efficiency and profitability.

- Laurus Labs is executing a new greenfield capex of 500 acres in Atchutapuram; specific timeline details to be shared next quarter. - Capex guidance has increased from INR 1,000 crores annually to approximately INR 1,500 crores annually, with an expectation to spend around INR 3,000 crores over the next two years. - Over 75% of recent investments focus on expansion of CDMO and CMO capabilities, with the remainder allocated to infrastructure like Effluent Treatment Plant (ETP) and maintenance. - Significant capex is dedicated to building large peptide manufacturing capacity; precise figures are not disclosed but described as "large." - New formulation facility commissioning in June includes tertiary packaging capacity aligned to a large existing CMO contract (3 billion tablets). - Vizag fermentation facility is expanding capacity in phases, aiming for up to 1 million liters capacity. - Capex projects have visibility with confirmed product and customer demand, minimizing speculative investments.

- No specific information on new fundraising through debt or equity mentioned for the current or immediate future. - Gross debt may slightly increase in FY '27 due to capex plans. - Capex guidance increased from INR 1,000 crore annually to INR 1,500 crore and projected INR 3,000 crore over next 2 years, mainly growth capex with visibility on projects/customers. - Debt-to-EBITDA ratio expected to remain stable or improve slightly despite higher gross debt. - Strong internal cash flows support capex and debt levels. - No mention of equity fundraising or new debt issuance plans.

- Soumya Chava mentioned that the order book for the next year is "pretty much in place," indicating strong visibility and continuity of orders. - Krishna Chaitanya Chava stated that while specific numbers are not disclosed, they have a robust pipeline of CDMO programs, including several late-stage and clinical programs with expected commercialization. - The company is confident about the growing order book in the CDMO segment and anticipates growth in FY '27, supported by these pipelines and ongoing projects. - They are cautious in giving specific quantitative visibility due to the clinical nature of products but express confidence in continued growth and commercialization. - Current capacities, including fermentation and peptide production, are being expanded to meet demand, reflecting strong order inflow and pipeline strength.